semaglutide cardiovascular news today SELECT Trial Semaglutide Improves Cardiovascular Outcomes in

Clinical trials show that semaglutide added to metformin produces substantial weight loss, with studies demonstrating reductions averaging 56 kg over 56 weeks at diabetes doses (1.0 mg weekly)

Pang X, Boucher W, Triadafilopoulos G, Sant GR, Theoharides TC

Lastly, we rationalize novel targets for further translational drug discovery and provide future perspectives

A licensed provider can help explore the underlying causes and guide you toward a safe, sustainable plan for reaching a healthier weight

Some patients may benefit from transitioning to alternative weight management medications or lower GLP-1 doses rather than complete discontinuation